Olympus Corporation of the Americas recalled the BF-H1100 bronchovideoscope on September 11, 2025, due to safety concerns when used with certain medical equipment. The recall affects 1,867 units distributed outside the U.S. Patients and healthcare providers should stop using the device immediately.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
The recalled product is the Olympus Bronchovideoscope, Model No. BF-H1100, with UDI 4953170424229. The recall affects 1,867 units distributed outside the U.S.
The recall addresses updates to the Instructions for Use (IFU) for the bronchovideoscope. The updates clarify safe and effective use when combined with laser, argon plasma coagulation, and high-frequency therapy equipment.
No incidents, injuries, or deaths have been reported related to this recall. The hazard level is classified as high.
Patients and healthcare providers must stop using the bronchovideoscope immediately. Follow the recall instructions provided by Olympus Corporation of the Americas.
For further instructions, contact Olympus Corporation of the Americas. Visit their website or call their customer service for assistance.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.